AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
TOKYO, Aug 1 Asia Pulse - Sankyo Co. (TSE:4501) said Tuesday that it has begun clinical testing in the U.K. of a new type of drug to treat diabetes.
CS-917 is an oral medication for the treatment of type 2 diabetes, a condition in which insulin is secreted, but does not lower blood sugar. The drug prevents the overproduction of sugar in the liver.